Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy

Søren Fast, Viveque Egsgaard Nielsen, Steen Joop Bonnema and Laszlo Hegedüs
Department of Endocrinology and Metabolism, Odense University Hospital, DK-5000 Odense C, Denmark
(Correspondence should be addressed to S Fast; Email: soeren.fast@ouh.regionsyddanmark.dk)

Abstract
The treatment of benign multinodular goitre (MNG) is controversial, but surgery is recommended in large compressive goitres. While some patients decline surgery others may have contraindications due to comorbidity, since MNG is prevalent in the elderly. Therefore, non-surgical treatment alternatives are needed. Until recently, levothyroxine therapy was the preferred non-surgical alternative, but due to low efficacy and potential side-effects, it is not recommended for routine use in recent international guidelines. Conventional radioiodine (131I) therapy has been used for two decades as an effective and safe alternative to surgery in the treatment of symptomatic non-toxic MNG. Since much higher activities of 131I are employed when treating non-toxic rather than toxic MNG, there has been reluctance in many countries to use this treatment modality. Frequently, the 131I-uptake in a non-toxic MNG is low, which makes 131I therapy less feasible. Another challenge is the negative correlation between the initial goitre size and goitre volume reduction (GVR). With its ability to more than double the thyroid 131I-uptake, recombinant human TSH (rhTSH) increases the absorbed radiation dose and thus enhances the GVR by 35–56% at the expense of up to fivefold higher rate of permanent hypothyroidism. An alternative strategy is to reduce the administered 131I-activity with a factor corresponding to the rhTSH induced increase in 131I-uptake. Hereby, the extrathyroidal irradiation can be reduced without compromising efficacy. Thus, although in its infancy, and still experimental, rhTSH-augmented 131I therapy may profoundly alter the non-surgical treatment of benign non-toxic MNG.

Introduction
Despite iodization programmes, simple goitre – defined as a euthyroid goitre that is not associated with thyroid autoimmunity or malignancy – still constitutes a major diagnostic and therapeutic challenge. Such goitres can be diffuse, uni- or multinodular (1). When applying ultrasound (US), most goitres have a nodular structure, particularly in the elderly (1). According to current thinking, they are caused by an interaction between genetic susceptibility and environmental triggers, iodine deficiency being the most important. There is no ideal treatment for benign multinodular goitre (MNG), as reflected by the lack of consensus in questionnaire surveys (2–5). Surgery is recommended when facing a large goitre or when malignancy cannot be ruled out (6, 7). However, it is important to recognise that a considerable proportion of patients refuse surgery, even in the context of a large symptomatic goitre, which underlines the need for non-surgical alternatives. The non-surgical treatment options are: iodine supplementation, levothyroxine (LT4) therapy and radioiodine (131I) therapy. In theory, percutaneous interventional therapy (laser photocoagulation or ethanol injection) is also an option in MNG, but so far it is only experimental and no controlled studies exist. At best, LT4 therapy has a minor effect on the appearance of new nodules but does not shrink the existing nodules (8). Due to low efficacy and accumulating evidence of cardiovascular and skeletal side-effects, it is not recommended for routine use in recent guidelines (6, 9) and reviews (7, 10). Iodine supplementation therapy is not superior to LT4 therapy and a major hindrance is the potential induction of hyperthyroidism (11). Conventional (without rhTSH) 131I therapy has been used for more than a decade in symptomatic non-toxic MNG, resulting in a mean thyroid volume reduction of ~40% 1 year after treatment (12) and 50–60% after 3–5 years (13). Generally, patient satisfaction is high and symptoms are considerably improved (14). A major drawback of this therapy is the need for relatively high activities of radioiodine when treating large goitres. Furthermore, the effect is attenuated with increasing goitre size (15). Another challenge is the frequent finding of a low (below 20%) thyroid radioiodine uptake (RAIU), caused mainly
by a high dietary iodine intake and/or by extensive degenerative changes within the thyroid gland.

The recent advent of recombinant human TSH (rhTSH) has opened new avenues for $^{131}$I therapy of MNG since it can double the thyroid RAIU even using minute quantities (16). In combination with $^{131}$I therapy rhTSH enhances the goitre volume reduction (GVR) by 35–56% (17–19) at the expense of up to fivefold higher rate of permanent hypothyroidism (18). Alternatively, the administered $^{131}$I-activity can be reduced by a factor corresponding to the rhTSH induced $^{131}$I-uptake increase, without compromising efficacy (20). The latter strategy of $^{131}$I therapy with reduced administered $^{131}$I-activity is intriguing, both in terms of minimizing the long-term risk of extrathyroidal malignancy and in reducing the cost and inconvenience of inpatient treatment. Here, we focus on non-surgical therapeutic aspects of simple MNG, including an update on rhTSH-augmented $^{131}$I therapy.

Clinical manifestations and natural history of benign non-toxic MNG

The aetiology, natural history and diagnostic evaluation of MNG has been thoroughly reviewed recently (7). In brief, the natural history of a nodular goitre is that of gradually increasing size with development of multiple nodules. However, the natural history with respect to growth and function varies and is difficult to predict in a given patient because no specific growth parameters exist. The annual growth rate is in the range of 0–20% and the 5-year incidence of hyperthyroidism is ~10% (7). Clinical manifestations of nodular goitre are related to those of growth or functional autonomy. Symptoms are typically those of local pressure (dysphagia, globulus sensation, cough or dyspnoea) or cosmetic complaints and are difficult to evaluate objectively. It is mandatory to rule out malignancy, for which purpose fine-needle aspiration biopsy is the golden standard (6). There is no simple relationship between goitre size and symptoms (14), which often makes the decision whether to treat or not difficult. In fact, one-third of clinicians would refrain from treatment facing a patient with moderate discomfort due to a multinodular non-toxic goitre of 50–80 g in which malignancy has been ruled out (2, 3). In asymptomatic subjects with relatively small goitres observation is acceptable, although many have a growth potential.

Non-surgical treatment of benign non-toxic MNG

Levothyroxine therapy

LT$_4$ therapy may have a role in the treatment of diffuse goitre, where clinically relevant goitre size reduction (15–40% after 3 months of therapy) has been documented in controlled trials (21–24). In uninodal goitre, results are conflicting, but there is a trend toward a positive effect in reducing nodule volume after 6–12 months of therapy (25). However, clinically relevant (more than 50%) nodule or goitre shrinkage occurs only in a minority of patients (10–20%). Even in the case of a modest effect, a matter of concern is the fact that studies (26, 27) have shown re-growth of nodules to baseline levels within 1 year of therapy cessation. Consequently, LT$_4$ therapy has to be continued for many years to benefit the patient. Little is known about long-term outcome and implications on quality of life (QoL). The only available controlled long-term study (28) showed no significant nodule size reduction after 5 years of continuous LT$_4$ therapy. In non-toxic MNG only three controlled trials exist, in which US was used for objective size monitoring (8, 26, 29). These studies have shown that the effect is at best very modest. Additionally, disqualifying LT$_4$ therapy, there is accumulating evidence of adverse effects on the skeleton and cardiovascular system. In a recent study, we have furthermore demonstrated that the vast majority (91%) of unselected consecutive Danish MNG patients are ineligible for LT$_4$ therapy, when applying the 2006 guidelines from the Endocrinologists and Associazione Medici Endocrinologi (30). Accordingly, LT$_4$ therapy is not recommended for routine use in recent guidelines and reviews (6, 7, 9, 10).

Iodine supplementation

Iodine supplementation can effectively reduce a diffuse goitre. In a controlled trial, performed in an iodine-deficient area, a daily dose of 400 µg iodine during 8 months was as effective as 150 µg LT$_4$ in reducing the size of endemic goitre (22). The majority of patients in that study had diffuse goitre and iodine supplementation has only been very scarcely evaluated in MNG patients, but it seems no better than LT$_4$ therapy (31). A major hindrance in the use of iodine supplementation is the fact that a sudden increase of the iodine intake may induce thyrotoxicosis in predisposed individuals (11). Furthermore, it is of concern that iodine supplementation appears to increase the incidence of papillary thyroid cancers and lymphocytic thyroiditis (32). Due to these major drawbacks it is disregarded as a therapeutic option in Europe (2) (except in Germany), as well as in North America (3).

Conventional (without rhTSH) radiiodine therapy for non-toxic MNG

Radioiodine has been used in the treatment of hyperthyroidism for over 60 years. In the last two decades the use has been widened to include symptomatic benign non-toxic goitre, resulting in a mean thyroid volume reduction of ~40% 1 year after
treatment (8,12, 13, 33) and 50–60% after 3–5 years (13). Approximately half of the effect is obtained within the first 3 months (13). A second 131I-dose may cause additional thyroid volume reduction (13). Considerable variation in GVR (15–70%) is obtained and for incompletely clarified reasons up to 20% of patients do not respond to 131I therapy (33). The superiority of 131I-treatment over LT4 therapy has been demonstrated in a randomized study by Wesche et al. (8). Only a few studies have investigated the effect of 131I-treatment in large goitres above 100 ml. In three studies in which a sensitive goitre monitoring was applied (i.e. computed tomography (CT) or magnetic resonance (MR) imaging the mean GVR was 30–40%, with considerable individual variation (15, 34, 35). Interestingly, these studies demonstrated that the GVR is inversely correlated to the initial goitre size (33). Another drawback when treating large goitres is the need for relative high 131I activities, thus requiring expensive and inconvenient inpatient treatment. Fractioned 131I therapy is an option in such patients (36), but due to potential thyroid stunning the doses should probably be given with wide intervals, thus rendering this treatment modality cumbersome.

Theoretically, the efficacy of 131I therapy depends mainly on the dose of absorbed radioactivity in the thyroid. When evaluating the outcome of different trials it should be remembered that results are difficult to compare due to variation in both the dose calculation method and in the method for determination of outcome (palpation, US, CT-scan or MRI) in terms of GVR. The issue concerning the optimal dose and dose planning for non-toxic MNG is controversial and much of the literature concerning dose selection deals with hyperthyroid patients (7). Generally, 131I-activities have been adjusted to RAIU, aiming at an absorbed thyroid dose of ~100 Gy (13, 15, 33), but others question whether this is worthwhile and instead use fixed-dose regimens, only taking thyroid size into consideration (7).

The adverse effects of conventional 131I therapy are well documented and described in detail elsewhere (7). Early adverse effects are in most cases mild and transient and include radiation induced thyroiditis (3%), transient hyperthyroidism (5%), Grave’s-like hyperthyroidism (5%) and occasionally a 15–25% increase of thyroid size. A late adverse effect of 131I therapy is the development of hypothyroidism, ranging from 22 to 58% within 5–8 years post 131I therapy. The long-term risk of extrathyroidal malignancy following 131I therapy for non-toxic MNG is unknown. In theory, this risk is higher in euthyroid MNG patients than in hyperthyroid patients, since higher activities of 131I are employed. Thus, a novel strategy using lower activities of 131I is desirable. It is however, reassuring that in a large survey in 35 593 hyperthyroid patients, mainly from the USA, followed up for a mean of 21 years, radiiodine therapy was not linked to total cancer deaths or any specific cancer, except for an increase in the standardized mortality ratio for cancer of the thyroid (37). The risk of thyroidal malignancy was assessed in a study of 5000 hyperthyroid patients during 27 years of follow-up (38). In that study, the risk of subsequent thyroid cancer was not significantly increased and bearing in mind that toxic MNG is a different stage of non-toxic MNG, this report is reassuring. But as indicated by the study of Metso et al. the issue is not finally laid to rest (39).

A major hindrance in the use of conventional 131I therapy in MNG is the frequent finding of a low (below 20%) thyroid RAIU. In this situation, 131I therapy is not feasible since high activities of radiiodine are needed to obtain an acceptable GVR. In such cases, the extrathyroidal irradiation increases and as a consequence the theoretical risk of long-term extrathyroidal malignancy. The thyroid RAIU is dependent on the dietary iodine intake and the extent of nodular autonomy (7). As a consequence of the widespread iodine enrichment programs a low thyroid RAIU is more often encountered.

RhTSH has been documented to increase the thyroid RAIU by more than twofold (20). With regard to the above-mentioned limitations of conventional 131I therapy, rhTSH has the potential to improve GVR – when using standard 131I activities (18) – or allow treatment with reduced 131I activities, without compromising efficacy. In the following we will explore these options.

**Radioiodine therapy with rhTSH pre-stimulation**

**Optimal rhTSH dose for enhancement of thyroid RAIU**

Since the initial reports on the effects of rhTSH on thyroid RAIU (40), efforts have focused on determining the optimal dose and timing for rhTSH administration. In the following, we will present the current knowledge on the dose and timing of rhTSH (Table 1).

The optimal dose of rhTSH for stimulation of thyroid RAIU remains to be established. Defining a lower dose limit that increases RAIU sufficiently is paramount, since adverse effects, especially the induction of transient thyrotoxicosis, are dose dependent (40–42). The changes in thyroid RAIU following rhTSH doses between 0.01 and 0.9 mg have been investigated in both healthy individuals and patients with MNG (Table 1). In our opinion, data from studies conducted in healthy individuals should not uncritically be applied to MNG patients, since the morphological changes in MNG may indicate an altered and/or delayed physiological response. Generally, studies are difficult to compare due to considerable variations in dietary iodine intake, baseline RAIU and goitre size. The lack of a control group in many studies also complicates the
interpretation. In addition, measurements of RAIU are extremely prone to variation in the method used. Despite these shortcomings, studies in MNG patients are extremely prone to variation in the method used. Studies in patients with multinodular goitre are also prone to variation, but usually less pronounced (43–46). It is unclear whether large goitres require higher doses of rhTSH for an optimal increase in RAIU.

The retained (effective) $^{131}$I-dose depends not only on the RAIU but also on the wash-out/release of $^{131}$I from the gland. So far, one study has investigated changes in the retained thyroid $^{131}$I-dose (48), with and without rhTSH. Following 0.3 mg of rhTSH, the retained thyroid $^{131}$I-dose was increased by 75% compared with placebo (48) (Fig. 1). Interestingly, the iodine kinetics during conventional (placebo group) $^{131}$I therapy resulted in a lower thyroid dose than the intended 100 Gy. The factors responsible for this phenomenon remain unidentified. A plausible explanation is increased iodine release from the gland during therapy and the possible impact from thyroid stunning (49). Apparently, rhTSH reverses this effect. The relative increase in 24 h RAIU (43%) was more effective than 2 h (relative median increase 90%) was more effective than 2 h (relative median increase 50%) (40).

Considering that the sodium–iodide-symporter is paramount.

Timing of rhTSH administration

Although scarcely investigated the optimal time interval between administration of rhTSH and $^{131}$I therapy seems to be 24 h (Table 1). However, this may be heavily influenced by the characteristics of the study/treatment population. One trial, studying 15 MNG patients, documented that an interval of 24 h (relative median increase in 24 h RAIU 90%) was more effective than 2 h (relative median increase in 24 h RAIU 50%) (40). Considering that the sodium–iodide-symporter is

### Table 1 The effect of recombinant human TSH (rhTSH) on thyroid radiiodine uptake (RAIU) and retained $^{131}$I-dose.

<table>
<thead>
<tr>
<th>Author</th>
<th>$n$</th>
<th>Study design</th>
<th>Dose rhTSH (mg)</th>
<th>Time interval between rhTSH and I-tracer</th>
<th>Baseline mean RAIU</th>
<th>Relative increase in mean RAIU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Huysmans et al. a</td>
<td>15</td>
<td>Open, non-controlled</td>
<td>0.01</td>
<td>2 h</td>
<td>24 h: 30%</td>
<td>24 h: 50% (median)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.01</td>
<td>24 h</td>
<td>24 h: 29%</td>
<td>24 h: 90% (median)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.03</td>
<td>24 h</td>
<td>24 h: 33%</td>
<td>24 h: 100% (median)</td>
</tr>
<tr>
<td>Nieuwiart et al. a</td>
<td>12</td>
<td>Open, non-controlled</td>
<td>0.01</td>
<td>24 h</td>
<td>24 h: 27%</td>
<td>24 h: 87%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.03</td>
<td>24 h</td>
<td>24 h: 22%</td>
<td>24 h: 145%</td>
</tr>
<tr>
<td>Duick et al. a</td>
<td>21</td>
<td>Open, non-controlled</td>
<td>0.1</td>
<td>0 h</td>
<td>24 h: 76%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.3</td>
<td>0 h</td>
<td>24 h: 77%</td>
<td></td>
</tr>
<tr>
<td>Silva et al. a</td>
<td>17</td>
<td>Open, non-controlled</td>
<td>0.45</td>
<td>24 h</td>
<td>24 h: 18%</td>
<td>24 h: 151%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2 × 0.1</td>
<td>24 h/0 h</td>
<td>24 h: 12%</td>
<td>24 h: 335%</td>
</tr>
<tr>
<td>Albino et al. a</td>
<td>18</td>
<td>Open, non-controlled</td>
<td>0.03</td>
<td>24 h</td>
<td>24 h: 26%</td>
<td>24 h: 68%</td>
</tr>
<tr>
<td>Cohen et al. a</td>
<td>17</td>
<td>Open, non-controlled</td>
<td>0.1</td>
<td>24 h</td>
<td>24 h: 18%</td>
<td>24 h: 174%</td>
</tr>
<tr>
<td>Paz-Filho et al. a</td>
<td>17</td>
<td>Open, non-controlled</td>
<td>0.1</td>
<td>24 h</td>
<td>24 h: 23%</td>
<td>24 h: 75%</td>
</tr>
<tr>
<td>Torres et al. a</td>
<td>6</td>
<td>Open, non-controlled</td>
<td>0.9</td>
<td>24 h</td>
<td>24 h: 25%</td>
<td>24 h: 88%</td>
</tr>
<tr>
<td>Pena et al. b</td>
<td>5</td>
<td>Open, non-controlled</td>
<td>0.1</td>
<td>24 h</td>
<td>24 h: 30%</td>
<td>24 h: 36%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.1</td>
<td>48 h</td>
<td>24 h: 30%</td>
<td>24 h: 0%</td>
</tr>
<tr>
<td>Lawrence et al. c</td>
<td>4</td>
<td>Open, non-controlled</td>
<td>0.9</td>
<td>8 h</td>
<td>16 h: 3.4%</td>
<td>16 h: 64%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.9</td>
<td>32 h</td>
<td>16 h: 3.2%</td>
<td>16 h: 100%</td>
</tr>
<tr>
<td>Nielsen et al.</td>
<td>35</td>
<td>Randomized placebo-controlled</td>
<td>0.3 placebo</td>
<td>24 h before therapy</td>
<td>24 h: 33%</td>
<td>24 h: 43%</td>
</tr>
<tr>
<td></td>
<td>28</td>
<td></td>
<td></td>
<td>24 h before therapy</td>
<td>24 h: 36%</td>
<td>24 h: –8%</td>
</tr>
</tbody>
</table>

a: Studies in patients with multinodular goitre.
b: Studies in healthy individuals.
c: Study in iodine loaded healthy men.
stimulated by rhTSH with some time delay (50), this is of no surprise. So far, intervals longer than 24 h have only been studied in healthy individuals, using 0.1 mg of rhTSH (41). This single study points at 24 h being the optimal interval, since it resulted in a mean increase in the 24 h RAIU from 25 to 47% (relative increase 88%) compared with 30–41% (relative increase 36%) using a 48 h interval and 30–31% (no significant increase) using a 72 h interval(41). These findings need to be confirmed in MNG patients, since the morphologic changes in a MNG may very well result in an altered physiological response (51).

Repetitive injections of rhTSH have been investigated in two trials (43, 52). In the first study, 0.1 mg of rhTSH was administered 0 h and 24 h respectively, before the 131I-tracer, resulting in a fourfold increase in 24 h RAIU (43). The second injection was probably close to the tracer administration to significantly influence the 24 h RAIU. The pronounced increase in RAIU in this study (43) may very likely be due to a low baseline RAIU (12.3%), more than due to repetitive rhTSH administration. From the aforementioned, we conclude that a 24 h interval between rhTSH injection and subsequent rhTSH, radioiodine and multinodular goitre

Effect on GVR

The potential benefits of rhTSH, when combined with 131I therapy, are those of increased GVR or reduced administered 131I-activity and thus reduced extrathyroidal irradiation. Combined with 131I therapy rhTSH increases the GVR in MNG patients by 35–56%. This effect has been documented in three randomized controlled trials (RCT) depicted in Table 2 (17–19). In small-to-medium sized goitres (median goitre volume 51 ml, range 20–99 ml), we demonstrated that 0.3 mg of rhTSH improved the mean GVR by 33% at 1 year follow-up (Fig. 2) (18). In another study, using 0.3 mg of rhTSH, but in large goitres (median goitre volume 160 ml, range 99–440 ml), the effect of rhTSH was even more pronounced. The average GVR was increased by 56% compared with conventional 131I therapy (Fig. 2) (17). In consistence with these two studies, Silva et al. (19), also treating large goitres (median goitre volume 219 ml, range 82–728) but with a fixed 131I activity (adjusted to thyroid size), demonstrated a 46% increase in mean GVR after pre-treatment with 0.45 mg rhTSH and a 12 month follow-up. The remaining non-controlled studies (Table 2) have demonstrated considerable GVR between 35 and 53% (20, 43, 44, 46, 52, 53), 6–12 months after rhTSH-augmented 131I therapy. Although lacking a control group, the results are promising since some of the latter studies (43, 46) were carried out in patients with relatively low baseline RAIU, thus demonstrating the feasibility of 131I therapy in such patients when employing rhTSH. One study, in 18 MNG patients with a baseline RAIU of 12%, documented a mean GVR of 39% after 6 months and 53% after 2 years (43, 54). Attaining acceptable GVR in patients with a low baseline RAIU is promising, since a high proportion of MNG patients are expected to have low RAIU due to iodization programmes. Before eradicating simple goitre by such programmes, the treatment of patients with existing goitre is in fact impeded.

Another approach is to reduce the administered 131I activity with a factor corresponding to the increase in RAIU obtained by rhTSH stimulation. This strategy was investigated in 22 MNG patients, using 0.01 or 0.03 mg of rhTSH (20). Pre-treatment with rhTSH allowed a 50% reduction of administered 131I activity, while still achieving a GVR of 40%, after 1 year. Such a reduced 131I activity is desirable both in terms of lowering the theoretical risk of late occurring extrathyroidal malignancy and in terms of being able to treat patients on an out-patient basis. Minimizing in-patient treatment reduces the economic burden to society and the inconvenience for the patient.
<table>
<thead>
<tr>
<th>Author (year)</th>
<th>n</th>
<th>Design</th>
<th>rhTSH dose (mg) and time interval</th>
<th>Goitre size estimation</th>
<th>Iodine dose</th>
<th>Mean goitre volume reduction</th>
<th>Myxoedema prevalence at follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nieuwlaat et al. (20) (2003)</td>
<td>12</td>
<td>Observational/non-controlled</td>
<td>0.01 0.03 0.03 24 h</td>
<td>MR-scan</td>
<td>Adjusted</td>
<td>35%/1 year 41%/1 year</td>
<td>33%</td>
</tr>
<tr>
<td>Duick et al. (53) (2003)</td>
<td>6</td>
<td>Observational/non-controlled</td>
<td>0.3 0.9 24 h</td>
<td>Palpation</td>
<td>Fixed 1110 MBq</td>
<td>30–40%/7 months 30–40%/7 months</td>
<td>50% 60%</td>
</tr>
<tr>
<td>Silva et al. (19) (2003)</td>
<td>34</td>
<td>Randomized/placebo-controlled</td>
<td>0.45 24 h</td>
<td>CT-scan</td>
<td>Fixed rhTSH: 58%/1 year placebo: 40%/1 year P&lt;0.05, between groups rhTSH: 58%/1 year placebo: 40%/1 year</td>
<td>65% placebo: 21%</td>
<td></td>
</tr>
<tr>
<td>Albino et al. (43) (2005)</td>
<td>18</td>
<td>Observational/non-controlled</td>
<td>2×0.1 24/48 h</td>
<td>CT-scan</td>
<td>Fixed 1110 MBq</td>
<td>39%/6 months 53%/2 years 34%/6 months</td>
<td>65% 72% 18%</td>
</tr>
<tr>
<td>Cohen et al. (44) (2006)</td>
<td>17</td>
<td>Observational/non-controlled</td>
<td>0.03 24 h</td>
<td>CT-scan</td>
<td>Fixed 1110 MBq</td>
<td>rhTSH: 44%/20 months Controls: 25%/22 months rhTSH: 17% Controls: 62%</td>
<td></td>
</tr>
<tr>
<td>Giusti et al. (52) (2006)</td>
<td>12</td>
<td>Observational/with matched controls</td>
<td>2×0.2 0 24/48 h</td>
<td>CT-scan</td>
<td>Fixed 370–555 MBq</td>
<td>rhTSH: 62%/1 year placebo: 46%/1 year P&lt;0.002, between groups rhTSH: 53%/1 year placebo: 34%/1 year P&lt;0.001, between groups rhTSH: 21% placebo: 7%</td>
<td></td>
</tr>
<tr>
<td>Nielsen et al. (18) (2006)</td>
<td>57</td>
<td>Double-blinded/randomized/placebo-controlled</td>
<td>0.3 24 h</td>
<td>US-scan</td>
<td>100 Gy adjusted</td>
<td>rhTSH: 61% placebo: 11%</td>
<td></td>
</tr>
<tr>
<td>Bonnema et al. (17) (2007)</td>
<td>29</td>
<td>Double-blinded/randomized/placebo-controlled</td>
<td>0.3 24 h</td>
<td>MR-scan</td>
<td>100 Gy adjusted</td>
<td>rhTSH: 53%/1 year placebo: 34%/1 year P&lt;0.001, between groups rhTSH: 21% placebo: 7%</td>
<td></td>
</tr>
<tr>
<td>Paz-Filho et al. (46) (2007)</td>
<td>17</td>
<td>Observational/non-controlled</td>
<td>0.1 24 h</td>
<td>CT-scan</td>
<td>Fixed 1110 MBq</td>
<td>46%/1 year 52%/2 years</td>
<td>53%</td>
</tr>
</tbody>
</table>

*Equality study, reduced $^{131}$I activity, aiming at the same absorbed dose as with conventional $^{131}$I therapy.

**Superiority study, aiming at increased thyroid irradiation.
rhTSH, radioiodine and multinodular goitre

Determinants of GVR

The theoretical foundation of rhTSH augmented $^{131}$I therapy is that of increased RAIIU leading to increased retained thyroid dose and irradiation. Based on three randomized controlled trials (17–19), pre-treatment with rhTSH beyond doubt improves GVR by 33–56% compared with conventional $^{131}$I therapy. But what are the mechanisms behind this enhancement? Employing conventional radiiodine therapy major determinants of GVR are: initial goitre size, retained thyroid dose and as yet unidentified individual susceptibility factors (33). In addition, it has been observed that the presence of dominant nodules (nodule volume > goitre volume) is related to a poorer response to $^{131}$I therapy and a higher risk of goitre recurrence (33). This indicates that the degree of morphological and/or functional changes, evidenced by US and thyroid scintigraphy, within the thyroid gland may affect the outcome of $^{131}$I therapy.

Initial goitre size and GVR

Using conventional non-rhTSH-stimulated $^{131}$I therapy, several studies have reported a negative correlation between initial goitre size and GVR (15, 33), and such a relationship is plausible, because a larger fraction of the gland may become inert and subsequently less susceptible to $^{131}$I. With the use of rhTSH this negative correlation seems to be abolished. In our recent controlled randomized study, we demonstrated that GVR was inversely correlated to the initial goitre volume in the placebo group, whereas such a correlation did not exist in the rhTSH group (18). A similar pattern was seen in the large goitre study (17) since only rhTSH stimulation had an impact on GVR, when a regression analysis was performed including rhTSH pre-stimulation, age, gender, use of antithyroid drug pre-treatment, thyroid 24 h $^{131}$I uptake at baseline, initial goitre volume and serum TSH before therapy.

Degree of morphological/functional changes

Pre-treatment with rhTSH may improve GVR by causing a more homogeneous distribution of radiiodine within the thyroid, especially increasing the uptake of $^{131}$I in

![Figure 2 Comparison of the relative goitre volume 1 year after conventional (placebo) and rhTSH augmented $^{131}$I therapy for non-toxic multinodular goitre, smaller and larger than 100 ml. Bars represent the relative mean goitre volume before therapy and 1 year after therapy. Adapted from Nielsen et al. (18) and Bonnema et al. (17).](https://www.eje-online.org)
scintigraphically relatively cold areas. In support of this theory, Nieuwlaat et al. (59) reported a trend toward a more homogeneous distribution of $^{131}$I, judged by scintigraphy and perhaps even an altered regional uptake, evidenced by cold areas becoming warm and vice versa. This observation has been confirmed by Albino et al. (43). These findings may very well explain the observation that the gain in GVR was more pronounced in large goitres (above 100 ml), since the degree of both morphological and functional changes within a goitre evolve with increasing goitre size (7).

A highly relevant but unanswered question is whether these rhTSH induced changes in regional RAIU result in a more pronounced nodule reduction, instead of paranoval tissue destruction. The higher prevalence of hypothyroidism with the use of rhTSH suggests that this may not be the case (18).

### Retained thyroid dose and GVR

The retained thyroid dose is positively correlated to GVR using conventional $^{131}$I therapy (17, 18, 33). In our double-blinded, randomized and controlled trial we found in the placebo group a significant positive correlation between the degree of goitre reduction and the retained thyroid dose (17). Such a correlation did not exist in the rhTSH group, implying that the goitre reduction was dependent on not only the thyroid dose but also other factors induced by rhTSH pre-stimulation (Fig. 3). In the study by Nielsen et al. (18) a similar pattern was found. By contrast, Albino et al. (43) found a positive correlation between the degree of GVR and the effective absorbed $^{131}$I-dose preceded by rhTSH-stimulation. As mentioned above, a plausible explanation for this additional rhTSH effect beyond the increase in RAIU could merely be a more homogenous distribution of $^{131}$I within the goitre. However, other, yet unidentified mechanisms behind such an effect, should it exist, could be an increased vulnerability to ionizing radiation of the rhTSH stimulated thyrocytes. In support of this theory, the cure rate, when hyperthyroid patients are treated with $^{131}$I, is positively correlated to the serum-TSH concentration (60).

Currently, the optimal dose of rhTSH is most likely below 0.1 mg, but it should be noted that the serum concentration of rhTSH may be an independent determinant for outcome in terms of GVR. The results of an ongoing phase 2 trial using 0.01 and 0.03 mg of modified release recombinant human TSH (MRrhTSH) as well as studies using different applied $^{131}$I doses to the thyroid will contribute to resolving these interesting issues.

Whether rhTSH influences the long term GVR or goitre recurrence rate is unclear. Follow-up results have only been scarcely reported, but following conventional $^{131}$I therapy Le Moli et al. found that 8% had recurrent goitre growth 3–5 years after therapy (33).

Although it is early to draw final conclusions, it is worth noting that the study by Bonnema et al. (17) documented a 56% GVR in large goitres, as opposed to the 35% in small goitres reported by Nielsen et al. (18). If this trend can be confirmed in future studies it indicates that patients with a very large goitre are possibly the best candidates for rhTSH-stimulated $^{131}$I therapy, especially if the baseline RAIU is low and surgery is disfavoured by the patient or the surgeon.

### Adverse effects of recombinant human TSH

RhTSH has been used in the treatment of differentiated thyroid cancer for more than a decade, and is generally well tolerated, even with repeated doses of 0.9 mg rhTSH. In large-scale clinical studies only a minority of patients had mild adverse reactions, such as nausea and headache (61). In combination with $^{131}$I therapy for MNG, acute and long-term alterations in thyroid function and size constitute the main adverse effects in patients with the thyroid gland in situ.

### Acute adverse-effects

The induction of transient dose dependent hyperthyroidism is the main adverse effect of rhTSH. The effects of rhTSH on thyroid function, both in healthy individuals and in patients with MNG, have been studied by us and others (40–42, 62, 63). Although different doses of rhTSH (0.01, 0.03, 0.3 and 0.9 mg) have been used, the same patterns in the various biochemical markers have been observed. Within 4–8 h of rhTSH injection, a rise in serum levels of thyroxine (T₄) and triiodothyronine (T₃) occurs, peaking at 24–48 h, followed by normalization within 3–4 weeks. A clear dose-response exists, since a more pronounced response in serum levels of T₄ and T₃ and thyroglobulin was observed when administering 0.3 mg rhTSH, compared with lower doses. A maximal stimulatory dose also seems to exist, since
0.9 mg rhTSH did not stimulate thyroid function more than 0.3 mg, when administered to the same subjects (42). With rhTSH doses of 0.01 and 0.03 mg the response is blunted and most patients maintain thyroid hormone levels within the normal range (20). Further reassuring is the observation that pre-treatment with 0.1 mg rhTSH did not affect structural and functional parameters of the heart, despite transient increases in serum levels of thyroid hormones (64). Thus, when limiting rhTSH doses to 0.1 mg or less, the rise in thyroid hormones seems to be of little clinical relevance. Nonetheless, caution is advised, especially when treating the elderly or patients with cardiovascular disease.

Acute swelling of the thyroid gland within the first 48 h following rhTSH injection has been documented in both healthy individuals and MNG patients. Likewise, tumour swelling and pain from metastases, resulting from repeated injections of 0.9 mg rhTSH have been reported in patients with differentiated thyroid carcinoma (65). Thus, 0.9 mg of rhTSH administered to nine healthy individuals resulted in a 35% increase in mean thyroid volume at 48 h (62). One individual developed a very profound and tender thyroid enlargement, from 22 to 90 ml. Similarly, when 0.3 mg of rhTSH was administered to 10 MNG patients, a mean volume increase of 24% was seen after 48 h (63). In susceptible individuals with a large obstructing goitre this may pose a serious threat in terms of respiratory problems. The concern of airway obstruction following rhTSH augmented 131I therapy is enhanced by the observation that conventional 131I-treatment itself may result in an acute increase in thyroid volume. Occasionally, thyroid size increase in the range of 15–25%, following conventional 131I-treatment, is seen (15, 66). If a synergistic effect of rhTSH and 131I on the thyroid swelling exists, combined therapy may pose a serious threat in predisposed individuals. Until now, only one study has evaluated whether rhTSH-augmented 131I therapy results in a significant acute goitre swelling (17). In our trial, using 0.3 mg of rhTSH, the average goitre volume remained unchanged 1 week after 131I therapy, but larger deviations from baseline were observed in patients pre-treated with rhTSH compared with placebo (17). The observations in that study are reassuring, but it should be kept in mind that the most pronounced deviations in thyroid size are seen in the first 48 h after rhTSH administration (62, 63).

Although observed in healthy individuals, the acute swelling of MNG tissue is probably dose dependent, since 0.1 mg of rhTSH resulted in a blunted (mean 10%) increase in thyroid volume, when administered to 25 healthy individuals (41).

Other adverse reactions, like cervical pain or tenderness, typically occurring in the first three weeks after treatment, are more frequent with the use of rhTSH (17–19). Most likely, these manifestations are a consequence of the increased thyroid irradiation, resulting in an increased incidence of radiation induced thyroiditis.

### Long-term adverse effects

Of more concern than the acute and transient increase in thyroid hormones, is the up to fivefold increase in the rate of permanent hypothyroidism when rhTSH is used in combination with 131I therapy (18). In the three randomized controlled trials, permanent hypothyroidism was reported in 21% (17), 61% (18) and 65% (19) of rhTSH treated patients, compared with 7% (17), 11% (18) and 21% (51) respectively, in the controls. Life-long LT4 therapy is needed in these individuals, and since there has been increasing focus on the possibility that hypothyroidism, even if treated with LT4, may result in reduced QoL (67), this issue is clearly of importance. Even so, the higher prevalence of hypothyroidism should not withhold clinicians from using rhTSH-augmented 131I therapy in view of the fact that the alternative (surgery) would also lead to hypothyroidism in the majority of cases. Whether the prevalence of hypothyroidism with rhTSH-augmented 131I therapy can be reduced without compromising efficacy (GVR) remains unclear. It is unsettled whether the increased incidence of hypothyroidism is solely caused by the increased absorbed 131I-dose, or if the rhTSH dose is an independent factor (48). As seen with conventional 131I therapy, the incidence of hypothyroidism is positively correlated to the GVR. Appearance of TSH receptor antibodies (TRAb) and/or anti-TPO antibodies has been reported in MNG patients following conventional 131I therapy (68). Apparently, the use of rhTSH does not increase this risk (69).

It is unclear whether rhTSH influences the long-term risk of thyroidal or extrathyroidal malignancy and only long-term follow-up studies can clarify this issue. In theory, this would depend on the strategy adopted. If the administered activity is not adjusted for the rhTSH induced increase in RAIU, the absorbed thyroid dose is increased (48) as is perhaps the long-term risk of thyroidal malignancy. On the other hand, one study has demonstrated that if the administered 131I activity is reduced according to the rhTSH induced increase in RAIU, the absorbed radiation-dose can be reduced in extrathyroidal organs and tissues, especially bladder and stomach (70).

### Future role and unresolved issues regarding the use of rhTSH in combination with 131I therapy

Pre-treatment with rhTSH beyond doubt improves GVR by 33–56% compared with conventional 131I therapy. Keeping in mind that rhTSH is used off-label in this setting we suggest that rhTSH may have a future role in 131I-treatment of MNG, especially in
large goitres or in goitres with a low RAIU. Doses of 0.01 and 0.03 mg are effective in increasing the RAIU, but it is too early to offer final recommendations as to the optimal dose of rhTSH. However, there is no evidence to support the use of doses above 0.1 mg. The results of an ongoing phase II trial, testing two low doses of modified release rhTSH in combination with $^{131}$I therapy, will help to clarify this issue.

Surgery remains the first line treatment for large compressive goitres, but rhTSH augmented $^{131}$I therapy is a promising new strategy in these patients. Another strong argument in favour of rhTSH is the potential to treat with a reduced $^{131}$I-activity without compromising efficacy. Considering that the issue of risk of extrathyroidal malignancy is not finally laid to rest, this strategy may be worthwhile. In addition, a reduced $^{131}$I-activity also implies that a higher proportion of patients can be treated on an out-patient basis.

Although rhTSH amplifies the GVR, the failure to demonstrate an effect on patient satisfaction or QoL is problematic (16). This issue deserves further attention to clarify whether it is due to lack of sensitivity of the method for QoL determination. Acute swelling of the thyroid gland has been reported with rhTSH doses above 0.1 mg, thus caution should be the rule when treating susceptible individuals with large and/or compressive goitres. This potentially serious side-effect is probably dose dependent, but further studies addressing this and other side-effects, including the long-term effect of the increased hypothyroidism rate, are needed. Most likely, the up to fivefold increase in the rate of permanent hypothyroidism goes hand-in-hand with the improved GVR, but strategies to optimise this imbalance should be explored. In our opinion, the relatively high rate of permanent hypothyroidism does not outweigh the beneficial effect of rhTSH, but points at the importance of identifying the obvious candidates for rhTSH pre-stimulation. Although LTh substitution therapy is regarded as a routine treatment without side-effects, there has been increasing focus on potential negative implications on QoL.

Future studies will clarify whether the serum rhTSH concentration is an independent factor for GVR. Also, it should be clarified whether rhTSH leads to a better nodule reduction or if the additional effect is mainly related to increased destruction of the ‘normal’ paramountular tissue. Finally, the risk of goitre recurrence after $^{131}$I therapy with and without rhTSH should be investigated.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this scientific work.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Acknowledgements

We would like to thank the Novo Nordic Foundation, The Agnes and Knut Mørk Foundation, The National Thyroid League, The A P Møller Relief Foundation, The Institute of Clinical Research (University of Southern Denmark), The Hans Skouby and wife Emma Skouby Foundation, Dagmar Marshall’s Foundation, Oda Pedersens Research Foundation, King Christian the X’s Foundation for supporting our clinical trials in this field over the last decade.

References


32. Harach HR & Williams ED. Thyroid cancer and thyroiditis in the goitrous region of Salta, Argentina, before and after iodine prophylaxis. *Clinical Endocrinology* 1995 43 701–706.


42. Torres MS, Ramirez I, Simkin PH, Braverman LE & Emerson CH. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. *Journal of Clinical Endocrinology and Metabolism* 2001 86 1660–1664.


45. Duick DS & Baskin HJ. Significance of radioiodine uptake at 72 hours versus 24 hours after pretreatment with recombinant human thyrotropin for enhancement of radioiodine therapy in patients with symptomatic nontoxic or toxic multinodular goiter. *Endocrine Practice* 2004 10 253–260.


www.eje-online.org
528 S Fast and others


51 Fast S, Grupe P, Nielsen VE, Bonnema SJ & Hegedus L. Influence of the interval (24, 48, or 72 hours) between the administration of 0.1 mg recombinant human thyrotropin (rhTSH) and subsequent thyroid radiodine uptake in nontoxic goiter patients. Evaluation by a randomized double-blinded trial. *ETA annual meeting*. Abstract No. 045, 2008.


54 Paz-Filho GJ, Mesa CO, Carvalho GA, Goedert CA & Graf H. Recombinant human TSH associated with radiiodine does not have further effects on thyroid volume and function after 2 years. *Clinical Endocrinology* 2008 69 345–346.


62 Nielsen VE, Bonnema SJ & Hegedus L. Effects of 0.9 mg recombinant human thyrotropin on thyroid size and function in normal subjects: a randomized, double-blind, cross-over trial. *Journal of Clinical Endocrinology and Metabolism* 2004 89 2242–2247.


66 Nygaard B, Faber J & Hegedus L. Acute changes in thyroid volume and function following $^{131}$I therapy of multinodular goitre. *Clinical Endocrinology* 1994 41 715–718.


